See more : Defense Technologies International Corp. (DTII) Income Statement Analysis – Financial Results
Complete financial analysis of Horizon Technology Finance Corporation (HRZN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Horizon Technology Finance Corporation, a leading company in the Asset Management industry within the Financial Services sector.
You may be interested
- GreenX Metals Limited (GRX.L) Income Statement Analysis – Financial Results
- Dawushan Farm Technology Co., Ltd. (6952.TW) Income Statement Analysis – Financial Results
- Jade Bird Fire Co., Ltd. (002960.SZ) Income Statement Analysis – Financial Results
- Eden Research plc (EDNSF) Income Statement Analysis – Financial Results
- Alice Queen Limited (AQX.AX) Income Statement Analysis – Financial Results
Horizon Technology Finance Corporation (HRZN)
About Horizon Technology Finance Corporation
Horizon Technology Finance Corporation is a business development company specializing in lending and and investing in development-stage investments. It focuses on making secured debt and venture lending investments to venture capital backed companies in the technology, life science, healthcare information and services, and cleantech industries. It seeks to invest in companies in the United States.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -9.87M | 26.64M | 33.27M | 10.33M | 21.30M | 14.90M | 12.40M | -1.76M | 14.97M | 20.85M | 7.23M | 7.32M | 14.78M | 15.33M | 16.36M |
| Cost of Revenue | 0.00 | 19.98M | 15.96M | 12.66M | 11.58M | -11.61M | 6.12M | 7.72M | 7.90M | 0.00 | 0.00 | -15.14M | 4.19M | 0.00 | 2.20M |
| Gross Profit | -9.87M | 6.66M | 17.31M | -2.33M | 9.72M | 26.51M | 6.28M | -9.48M | 7.06M | 20.85M | 7.23M | 22.46M | 10.59M | 15.33M | 14.15M |
| Gross Profit Ratio | 100.00% | 25.01% | 52.03% | -22.54% | 45.63% | 177.93% | 50.66% | 539.00% | 47.20% | 100.00% | 100.00% | 306.73% | 71.64% | 100.00% | 86.54% |
| Research & Development | 0.00 | 0.30 | 0.49 | 0.20 | 0.50 | 0.41 | 2.10 | -0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.67M | 4.78M | 4.69M | 3.75M | 3.41M | 3.04M | 2.87M | 3.24M | 3.46M | 5.26M | 3.48M | 3.10M | 3.45M | 321.00K | 321.51K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.67M | 4.78M | 4.69M | 3.75M | 3.41M | 3.04M | 2.87M | 3.24M | 3.46M | 5.26M | 3.48M | 3.10M | 3.45M | 321.00K | 321.51K |
| Other Expenses | 0.00 | -9.38M | 395.00K | -2.64M | -1.85M | -6.36M | -5.17M | -5.88M | -3.95M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 274.38K |
| Operating Expenses | 21.57M | 4.78M | 5.08M | 3.75M | 1.56M | 1.86M | 2.79M | 3.24M | 3.11M | 5.26M | 3.48M | 3.10M | 3.45M | 321.00K | 595.89K |
| Cost & Expenses | 21.57M | 4.78M | 5.08M | 3.75M | 1.56M | 1.86M | 2.79M | 3.24M | 3.11M | 5.26M | 3.48M | 3.10M | 10.65M | 321.00K | 2.80M |
| Interest Income | 110.13M | 77.37M | 54.41M | 42.19M | 37.09M | 28.79M | 23.76M | 31.40M | 28.65M | 28.64M | 31.90M | 25.29M | 22.97M | 14.99M | 4.24M |
| Interest Expense | 28.97M | 19.20M | 12.03M | 9.67M | 8.33M | 6.36M | 5.17M | 5.88M | 5.76M | 8.71M | 8.12M | 4.28M | 2.68M | 4.25M | 4.24M |
| Depreciation & Amortization | 0.00 | 29.35M | 16.56M | 15.30M | 11.12M | 18.73M | -5.03M | 30.21M | 5.76M | 8.71M | 8.12M | 4.28M | -2.40M | 0.00 | 0.00 |
| EBITDA | 11.94M | 0.00 | 0.00 | 0.00 | 0.00 | 19.41M | 9.62M | 22.89M | 0.00 | -3.99M | -9.76M | 16.51M | 14.64M | 14.73M | 13.56M |
| EBITDA Ratio | -120.93% | 154.15% | 84.72% | 63.74% | 92.66% | 128.05% | 140.36% | -1,301.31% | 131.99% | 93.95% | 299.28% | 225.52% | 94.82% | 97.91% | 82.89% |
| Operating Income | -1.34M | 41.07M | 28.18M | 6.59M | 19.74M | 24.66M | 12.32M | 17.01M | 14.00M | 10.88M | 13.51M | 12.23M | 16.42M | 15.01M | 13.56M |
| Operating Income Ratio | 13.56% | 154.15% | 84.72% | 63.74% | 92.66% | 165.48% | 99.34% | -967.14% | 93.52% | 52.18% | 186.90% | 167.01% | 111.05% | 97.91% | 82.89% |
| Total Other Income/Expenses | -14.36M | -23.09M | -7.54M | -8.34M | -6.07M | -6.04M | -7.87M | -22.01M | -7.90M | -3.99M | -17.89M | -12.29M | -2.07M | 0.00 | -4.24M |
| Income Before Tax | -15.70M | 21.87M | 28.18M | 6.59M | 19.74M | 13.04M | 9.62M | -5.00M | 11.86M | 15.59M | 3.75M | 4.22M | 11.34M | 0.00 | 9.31M |
| Income Before Tax Ratio | 159.00% | 82.07% | 84.72% | 63.74% | 92.66% | 87.54% | 77.52% | 284.25% | 79.22% | 74.79% | 51.85% | 57.67% | 76.69% | 0.00% | 56.94% |
| Income Tax Expense | 1.49M | 715.00K | 401.00K | 222.00K | 239.00K | 34.00K | 25.00K | -87.00K | 0.00 | 160.00K | 240.00K | 231.00K | 340.00K | 0.00 | -9.31M |
| Net Income | -17.19M | 21.15M | 27.78M | 6.36M | 19.50M | 13.01M | 9.59M | -4.91M | 11.86M | 15.43M | 3.51M | 3.99M | 11.00M | 0.00 | 9.31M |
| Net Income Ratio | 174.10% | 79.39% | 83.51% | 61.60% | 91.54% | 87.32% | 77.32% | 279.31% | 79.22% | 74.02% | 48.53% | 54.51% | 74.39% | 0.00% | 56.94% |
| EPS | -0.56 | 0.86 | 1.39 | 0.36 | 1.45 | 1.13 | 0.83 | -0.43 | 1.06 | 1.60 | 0.37 | 0.47 | 1.44 | 0.00 | 1.23 |
| EPS Diluted | -0.56 | 0.86 | 1.39 | 0.36 | 1.45 | 1.13 | 0.83 | -0.43 | 1.06 | 1.60 | 0.37 | 0.47 | 1.44 | 0.00 | 1.23 |
| Weighted Avg Shares Out | 30.96M | 24.73M | 20.03M | 17.53M | 13.48M | 11.53M | 11.52M | 11.54M | 11.18M | 9.62M | 9.58M | 8.48M | 7.61M | 0.00 | 7.56M |
| Weighted Avg Shares Out (Dil) | 30.96M | 24.73M | 20.03M | 17.53M | 13.48M | 11.53M | 11.52M | 11.54M | 11.18M | 9.62M | 9.58M | 8.48M | 7.61M | 0.00 | 7.56M |
Want to Make $10,000 in Passive Income This Year? Invest $100,000 in These 3 Ultra-High-Yield Dividend Stocks.
Hercules Technology is a consistently high-performing BDC stock with a 10.3% yield. Horizon Technology operates across a variety of high-growth industries and is a proven multibagger over a long-term horizon.
BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC.
VANCOUVER, BC , Feb. 21, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce has completed the acquisition of the entire portfolio of discovery, preclinical and clinical development stage assets...
Horizon Technology Finance to Announce Fourth Quarter 2023 Financial Results
FARMINGTON, Conn. , Feb. 13, 2024 /PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ: HRZN) ("Horizon") (the "Company"), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed...
Horizon Technology Finance (HRZN) Ascends While Market Falls: Some Facts to Note
Horizon Technology Finance (HRZN) closed at $13.29 in the latest trading session, marking a +0.61% move from the prior day.
BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.
VANCOUVER, BC , Feb. 12, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that it has executed the definitive Asset Purchase Agreement dated February 11 th, 2024 to acquire the entire portfolio...
What's Wrong With These 7%+ Yields That Wall Street Hates?
When the Wall Street cheerleaders actually dislike a stock—well, that sure commands our contrarian attention.
Horizon Technology Finance (HRZN) Falls More Steeply Than Broader Market: What Investors Need to Know
Horizon Technology Finance (HRZN) closed at $13.27 in the latest trading session, marking a -0.82% move from the prior day.
Horizon Technology Finance (HRZN) Stock Sinks As Market Gains: Here's Why
In the most recent trading session, Horizon Technology Finance (HRZN) closed at $13.24, indicating a -0.15% shift from the previous trading day.
Horizon Technology: A 10% Yield For Long-Term Investors
Horizon Technology Finance is a well-run BDC that invests in neglected technology and life sciences companies. The BDC focuses on a small number of industries, providing secured loans to venture capital-backed companies. HRZN has seen a strong trend in net...
Horizon Technology: New Year, More Monthly Dividends
Horizon Technology Finance offers investors monthly dividend payments, providing recurring income to match fund living expenses. The stock has performed well, outperforming the S&P 500 and other peers in the past decade. HRZN has a healthy payout ratio and potential...
Source: https://incomestatements.info
Category: Stock Reports